Lee AY, Kim MJ, Chey WY, Choi J, Kim BG. Just because a medication interacts with one substrate of a particular cytochrome P450 pathway, does not mean it affects all … Seven M, Batar B, Unal S, Yesil G, Yuksel A, Guven M. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children. You can learn about our use of cookies by reading our If you agree to our use of cookies and the contents of our Privacy Policy please click 'accept'. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Chung W-H, Chang W-C, Lee Y-S, et al. Ieiri I, Goto W, Hirata K, et al. Aynacioglu AS, Brockmöller J, Bauer S, et al. Cerebellar atrophy after acute phenytoin intoxication. Feedback Form Suggest a Drug. Spell. Upgrade to remove ads. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Caudle KE, Rettie AE, Whirl-Carrillo M, et al. Klotz U. Log in Sign up. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C9 in Tamilnadu population. Chang C-C, Ng C-C, Too C-L, et al. Ohmori H, Kobayashi T, Yasuda M. Neurotoxicity of phenytoin administered to newborn mice on developing cerebellum. Lakhan R, Kumari R, Singh K, Kalita J, Misra UK, Mittal B. Comparison and predictors of rash associated with 15 antiepileptic drugs. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Jose R, Chandrasekaran A, Sam SS, et al. The Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing and the US Food and Drug Administration proposed that neither PHT nor fosphenytoin should be used in these patients.It is also very important to consider the interactions of PHT with other drugs.PHT meets all the pharmacogenomic prerequisites necessary for change in drug effect to be considered clinically important, as proposed by MacKenzie and Hall:Future use of pharmacogenomics, particularly for the intensive care unit patients, will be more helpful, given our current inability to predict either the efficacy or the occurrence of unwanted adverse effects of drugs in a population at high risk of being administered large doses of drugs, usually as an IV bolus, more prone to severe adverse effects and with little physiological reserve to compensate them.PHT is a very effective drug to treat epilepsy and one of the best options for treating status epilepticus, but its dosages should be individualized to reduce the risk of side effects that could justify its withdrawal, even when effective. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. olodaterol paclitaxel repaglinide torsemide. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Farmacogenética, farmacogenómica y terapia antiepiléptica individualizada [Pharmacogenetics, pharmacogenomics and individualised antiepileptic therapy]. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Cookies help … Create . Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Learn vocabulary, terms, and more with flashcards, games, and other study tools. Apps. The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC
Introduction. Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Browse. Applications of CYP450 testing in the clinical setting. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Gravity. A large number of studies have demonstrated a marked variation in the frequency distribution of CYP2C9 alleles around the world, with the wild-type allele frequency ranging from 76.5 to 96.7%.Subsequent studies on individuals identified with variants CYP2C9 *2 and CYP2C9 *3 showed significantly reduced enzymatic activity,Other variants are rare and have been reported in different ethnic groups; the CYP2C9 *4 is an extremely rare variant identified in Japanese epileptic patients,Some studies showed a statistically significant increase in blood level of PHT in patients with epilepsy and alleles CYP2C9 *2 and CYP2C9 *3, compared to patients with the wild-type genotype (The CYP2C19 gene is also responsible for the metabolization of PHT to a lesser extent (10%). Yukawa E, Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.